Wednesday, 15 Aug 2018

You are here

IL-1 Suppression May Improve Dilated Cardiomyopathy


Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

The 57-year-old man with a 2-year history of DCM had been hospitalized for chronic fatigue and dyspnea secondary to heart failure (New York Heart Association class III). Transthoracic echocardiography (TTE) showed a severely dilated left ventricle; left ventricular ejection fraction (LVEF) was 28%. Cardiac catheterization showed normal coronary arteries.

After 6 months of optimal medical therapy, the patient remained symptomatic - - TTE again showing a severely dilated left ventricle.

With no autoantibodies in blood or viral genome sequences in endomyocardial biopsy, he was determined to meet criteria for idiopathic inflammatory DCM, Giulio Cavalli, MD, of San Raffaele Scientific Institute in Milan, Italy, and colleagues reported online in the Annals of Internal Medicine.

The patient was then started on subcutaneous injections of anakinra (Kineret, the recombinant form of the endogenous antagonist for the interleukin-1 receptor) - - and "the clinical response was striking," Cavalli's group said.

Within 2 weeks, the patient improved to New York Heart Association class I and had LVEF climb to 38%.

Four weeks in, LVEF rose even further, to 42%. There was no change in myocardial scarring, but myocardial edema nearly resolved and ventricular ectopic beats almost disappeared. A decrease in the serum interleukin-6 level (a measure of the amount of inflammation sustained by interleukin-1) confirmed that anakinra had effectively suppressed the inflammation, the researchers reported.

"This patient with DCM experienced what we believe to be unprecedented clinical improvement with use of anakinra to inhibit interleukin-1. Improvement began soon after anakinra administration and was obvious by every measure. The patient felt better and was able to lead a more normal life," they said.

Much is already known about the safety of anakinra from patients with rheumatologic conditions, according to Cavalli and colleagues, who said they believed "that this treatment and the role of chronic low-grade inflammation in DCM deserve further investigation."The inflammatory hypothesis in cardiovascular disease was validated last year in the CANTOS trial, in which another anti-inflammatory monoclonal antibody, canakinumab (Ilaris), reduced cardiovascular events by 15%.

That drug carries a cost of $16,000 per injection, which was once every 3 months in CANTOS. Anakinra, at the standard 100 mg per day dose, retails for about $1,000 per week.

Cavalli reported personal fees from SOBI and Novartis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.

EULAR 2018 - Day 4 Report

The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters.  In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports. Also some of these represent research and reporting trends – some healthy, others not so – that were evident at the EULAR 2018 meeting.